Theralase Technologies Inc. is focused on developing and commercializing therapeutic laser technology and cancer treatments. They are launching an upgraded laser system called the TLC-2000 in Q1 2014 that will provide recurring revenue through monthly treatment fees. This system has been proven effective in clinical studies for pain, inflammation, and other conditions. Theralase also has patented photo dynamic compounds for non-invasive cancer destruction now undergoing preclinical and clinical trials. The company is seeking a $3M private placement to expand their laser center network internationally and in major US cities starting in 2014 to increase sales of their FDA-approved laser technology.

1. HEALING AT THE SPEED OF LIGHT
August 1,2013
$0.25
$0.30
$0.145
7,531
CURRENT
52 WEEK HIGH
52 WEEK LOW
AVG. VOLUME
Investment Opportunity:
Participation in a $3 M Private Placement Theralase Technologies Inc. (TSXV: TLT)
Theralase Technologies Inc. is focused on a two‐part strategy:
1. Production, marketing and distribution of the FDA approved and proprietary Theralase Superpulsed Laser technology for sale
to health care practitioners that are dedicated to the treatment of chronic pain, inflammatory conditions, sports injuries and
wounds. In 1Q 2014, Theralase plans to launch the patented TLC‐2000 biofeedback laser system in Canada and USA to provide a
quantum leap forward in therapeutic laser technology and to introduce the first recurring revenue model in a therapeutic laser.
2. Commercialization of patented cancer technology through preclinical research, human clinical trials and regulatory approvals
in the direct destruction of cancer utilizing Theralase’s advanced new class of light activated Photo Dynamic Compounds (PDC)
Therapeutic Laser Technology (TLT) Division
Opportunity:
• Launch a patented, next generation therapeutic laser system in Canada and the US in 1Q 2014
• Theralase will employ a recurring revenue model; whereby, the company will provide the technology, training,
certification, service and customer referrals, in exchange for an initial upfront fee and monthly treatment fee based upon usage
Upside:
• $21 M a year therapeutic laser recurring revenue model in 3 years with 50% net margin
• FDA approved, non-invasive, treatment of chronic pain and inflammation
• World market exceeds $100 billion annually
• Proven effective in blinded, randomised, controlled clinical studies
• Incorporates TENS (Transcutaneous Electrical Nerve Stimulation) to allow additional CPT billing codes for the US market
• Cumulative ROI: 1.5 Year: 200%, 2.5 Years: 300%, 3.5 Years: 700%
Intellectual Property
Therapeutic Laser Patents: USA Patent: 6,413,267, Canadian Patent: 2,315,521, Belgium, Italy, Great Britain, Germany, France,
Spain Patent: 1075854
Why Invest?
• International Patented Technology
• Large Market Opportunity
For more information, please contact Mr. Roger White, President and CEO, 1-866-843-5273, x:225 rwhite@theralase.com
This executive summary contains forward-looking statements, which reflect the Company's current expectations regarding future events.The forward-looking statements involve
risks and uncertainties. Actual results could differ materially from those projected herein.
Company
• Designs, develops and manufactures patented, superpulsed laser technology
• > 90% efficacy on a wide range of neural muscular skeletal conditions (i.e.: Low Back Pain, Knee Osteoarthritis, Shoulder Tendonitis)
• Solid business built in Canada over the last 20 years consistently producing annual revenues of approximately $2 million with a
flat bottom line.
• Investments into next generation therapeutic laser technology and next generation cancer therapy have led to a loss of
approximately $1.0 to $1.5 M annually.
• 80% of sales completed in Ontario.
Opportunity:
Expansion of sales and marketing into Western Canada, the 5 largest states in the US (30% of US GDP and population) and other
international markets with Theralase Laser Centres covering overhead.
Strategy:
• Launch Theralase Laser Centre / Sales and Marketing Office in Toronto, Ontario – May 2013 (Complete)
• Launch Theralase Laser Centre / Sales and Marketing Office in Calgary, Alberta – September 2013
• Launch Theralase Laser Centre / Sales and Marketing Office in Manhattan, New York – March 2014
• Launch Theralase Laser Centre / Sales and Marketing Office in Los Angeles, California – March 2014
• Launch Theralase Laser Centre / Sales and Marketing Office in Tampa, Florida – June 2014
• Launch Theralase Laser Centre / Sales and Marketing Office in Houston, Texas – June 2014
• Launch Theralase Laser Centre / Sales and Marketing Office in Chicago, Illinois – September 2014
TSXV:TLT
• Experienced Management Team and Advisors to Execute Strategy
• Attractive ROI